Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -0.32% is 99% above its 5-year average of -50.37%, near the high end of its 5-year range (-96.81%–-0.32%).
As of the fiscal period ended Tuesday, June 30, 2026. 99.21% above its 12-month average of -40.80%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -0.32%.
RETURN ON INVESTED CAPITAL (ROIC)
-0.32%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-40.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-76.70%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-50.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-51.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+99.21%
CURRENT VS 3Y AVG
+99.58%
CURRENT VS 5Y AVG
+99.36%
CURRENT VS 10Y AVG
+99.37%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
+99.09%
vs the sector median at left
Enlivex Therapeutics Ltd.
Market Cap
$5.73M
Return on Invested Capital (ROIC)
-0.32%
TTM Avg
-40.80%
3Y Avg
-76.70%
5Y Avg
-50.37%
Market Cap
$5.70M
Return on Invested Capital (ROIC)
-80.65%
TTM Avg
-65.64%
3Y Avg
-61.70%
5Y Avg
-66.02%
Market Cap
$5.82M
Return on Invested Capital (ROIC)
-84.15%
TTM Avg
-84.15%
3Y Avg
-84.15%
5Y Avg
-84.15%
Market Cap
$5.63M
Return on Invested Capital (ROIC)
-94.08%
TTM Avg
-1223.16%
3Y Avg
-731.00%
5Y Avg
-532.24%
Market Cap
$5.83M
Return on Invested Capital (ROIC)
-122.15%
TTM Avg
-90.24%
3Y Avg
-109.34%
5Y Avg
-347.01%
Market Cap
$5.89M
Return on Invested Capital (ROIC)
-10.98%
TTM Avg
-32.05%
3Y Avg
-35.21%
5Y Avg
-35.46%
Market Cap
$5.92M
Return on Invested Capital (ROIC)
-82.84%
TTM Avg
-84.28%
3Y Avg
-109.54%
5Y Avg
-250.89%
Market Cap
$5.35M
Return on Invested Capital (ROIC)
-175.26%
TTM Avg
-258.55%
3Y Avg
-208.94%
5Y Avg
-173.09%
Market Cap
$6.11M
Return on Invested Capital (ROIC)
-15.99%
TTM Avg
-17.35%
3Y Avg
-65.46%
5Y Avg
-66.42%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. (ENLV) | $5.73M | -0.32% | -40.80% | -76.70% | -50.37% |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | -80.65% | -65.64% | -61.70% | -66.02% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | -84.15% | -84.15% | -84.15% | -84.15% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -94.08% | -1223.16% | -731.00% | -532.24% |
| Lucyd, Inc (LUCY)vs › | $5.83M | -122.15% | -90.24% | -109.34% | -347.01% |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | -10.98% | -32.05% | -35.21% | -35.46% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.92M | -82.84% | -84.28% | -109.54% | -250.89% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -175.26% | -258.55% | -208.94% | -173.09% |
| Scienture Holdings, Inc. (SCNX)vs › | $6.11M | -15.99% | -17.35% | -65.46% | -66.42% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -27.41% | -21.46% | -17.98% | -12.44% |
ROIC
-0.3%
ROE
105.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -0.32% |
| 2025-12-31 | -0.50% |
| 2025-09-30 | -82.65% |
| 2025-06-30 | -79.72% |
| 2025-03-31 | -73.09% |
| 2024-12-31 | -65.67% |
| 2024-09-30 | -75.50% |
| 2024-06-30 | -78.80% |
| 2024-03-31 | -96.81% |
| 2023-12-31 | -95.53% |
| 2023-09-30 | -63.16% |
| 2023-06-30 | -56.11% |
| 2023-03-31 | -47.97% |
| 2022-12-31 | -42.27% |
| 2022-09-30 | -37.96% |
| 2022-06-30 | -32.75% |
| 2022-03-31 | -26.41% |
| 2021-12-31 | -21.33% |
| 2021-09-30 | -16.24% |
| 2021-06-30 | -14.64% |
| 2021-03-31 | -12.84% |
| 2020-12-31 | -27.19% |
| 2020-09-30 | -30.78% |
| 2020-06-30 | -29.87% |
| 2020-03-31 | -25.23% |
| 2019-12-31 | -74.43% |
| 2019-09-30 | -53.51% |
| 2019-06-30 | -44.58% |
| 2019-03-31 | -45.42% |
| 2018-12-31 | -53.50% |
| 2018-09-30 | -34.17% |
| 2018-06-30 | -234.23% |
| 2017-12-31 | -188.33% |
| 2017-09-30 | -225.39% |
| 2017-06-30 | -252.92% |
| 2017-03-31 | -223.58% |
| 2016-12-31 | -182.39% |
| 2016-09-30 | -155.00% |
| 2016-06-30 | -107.41% |
| 2016-03-31 | -82.00% |
| 2015-12-31 | -85.97% |
| 2015-09-30 | -62.46% |
| 2015-06-30 | -49.21% |
| 2015-03-31 | -34.71% |
| 2014-12-31 | -23.08% |
| 2014-09-30 | -13.98% |
| 2014-06-30 | -71.80% |
